Article
Chemistry, Multidisciplinary
D. Das, S. Basu, N. Rana, S. Roy, B. Hazra, K. Sen
Summary: This study presents a hassle-free, rapid, and green synthesis method for a novel fluorosensor CuI@graphene nano-composite (CuI@Gr) for antibody-free optical sensing of prostate-specific antigen (PSA), a biomarker for prostate cancer. The CuI@Gr nanoparticles showed enhanced efficacy in detecting PSA in serum medium with a ten-fold lower limit of detection (0.331 pg/mL) compared to CuI nanoparticles. Moreover, the CuI@Gr nanoparticles demonstrated improved detection efficiency even in the presence of interfering biomolecules such as glucose and cholesterol, commonly found in serum due to comorbidities.
MATERIALS TODAY CHEMISTRY
(2022)
Article
Urology & Nephrology
Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Ove Gustafsson
Summary: The study examined the long-term association between baseline PSA levels and risk of prostate cancer death after 30 years. Results showed that the risk of prostate cancer death increases with higher baseline PSA levels, but is significantly decreased in men with PSA levels below 2.0 ng/mL and f/t PSA ratio of >= 0.25.
Article
Oncology
Naseruddin Hoti, Tung-Shing Lih, Mingming Dong, Zhen Zhang, Leslie Mangold, Alan W. Partin, Lori J. Sokoll, Qing Kay Li, Hui Zhang
Summary: Prostate cancer is a leading cause of death in men in the United States. The commonly used method of diagnosis involves digital rectal examination and serum PSA assay, followed by prostate gland biopsy. However, false elevations in PSA levels can lead to unnecessary biopsies. This study evaluated the use of urinary PSA as a predictive marker for aggressive prostate cancer, and found that it had higher predictive power compared to serum PSA. Combining serum and urinary PSA levels further enhanced the detection of aggressive prostate cancer.
Article
Biochemistry & Molecular Biology
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.
Article
Chemistry, Analytical
Juliette M. Cazanave Mora, Ruben del Valle Garcia, Lilian Perez Lopez, Dunia C. Bequer Ariza, Orlando Zulueta Rodriguez, Antonio Melchor Rodriguez, Liliana Hernandez Perez, Raquel Lopez Cisneros, Ana L. Arteaga Yera, Eladio Silva Cabrera, Jose L. Fernandez Yero
Summary: Prostate specific antigen (PSA) is measured using a sandwich-type UltraMicro Enzyme-Linked ImmunoSorbent Assay (UMELISA) that can detect both total PSA (tPSA) and free PSA (fPSA) in human serum samples. The assay shows good analytical performance and correlation with other commercial methods. A retrospective study in Cuba demonstrated the affordability and usefulness of UMELISA PSA as a diagnostic assay for the Cuban Public Health System and developing countries.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2022)
Article
Biochemical Research Methods
Canan Ozyurt, Inci Uludag, Mustafa Kemal Sezginturk
Summary: This study developed a disposable electrochemical aptasensor based on ITO-PET film for sensitive and selective detection of prostate-specific antigen (PSA) in real serum samples. The biosensor exhibited excellent sensitivity, precision, repeatability, and storage stability, making it a potential candidate for clinical applications.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2023)
Article
Chemistry, Analytical
Daniel Mwanza, Nololo Mfamela, Omotayo Adeniyi, Tebello Nyokong, Philani Mashazi
Summary: This study achieved the preparation of glucose encapsulating nanoliposomes using two different lipid formulations. The F2 formulation showed the highest controlled release at acidic pH and was used for the indirect detection of PSA. The PGM system had the lowest limit of detection due to its sensitivity to glucose. The Pd | PdO nanozyme system demonstrated good stability at high temperatures.
Article
Urology & Nephrology
Kendrick Yim, Chaoran Ma, Sigrid Carlsson, Hans Lilja, Lorelei Mucci, Kathryn Penney, Adam S. Kibel, Scott Eggener, Mark A. Preston
Summary: Adding percent free PSA to total PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA can be used to stratify risk in screening and reduce unnecessary prostate biopsies.
JOURNAL OF UROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Youngjun Boo, Jae Hoon Chung, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Wan Song
Summary: As the incidence of prostate cancer has increased, there is controversy surrounding the use of prostate-specific antigen (PSA) for screening due to its low specificity. In this study, we compared the diagnostic performance of prostate health index (PHI) density (PHID) with PSA, PSA density (PSAD), and PHI as a triaging test for the detection of prostate cancer and clinically significant prostate cancer (csPCa). The results showed that PHID had the highest area under the curve (AUC) for both prostate cancer and csPCa detection, followed by PHI, PSAD, and PSA. Using PHID as a triaging test could significantly reduce unnecessary biopsies for prostate cancer. The findings suggest that PHID can be utilized in a clinical setting to assess the risk of prostate cancer and csPCa.
Review
Medicine, General & Internal
Samuel W. D. Merriel, Lucy Pocock, Emma Gilbert, Sam Creavin, Fiona M. Walter, Anne Spencer, Willie Hamilton
Summary: The evidence currently available suggests that PSA is highly sensitive but poorly specific for detecting prostate cancer in symptomatic patients. However, limitations in study design and reference test reduce the certainty of this estimate. There is limited evidence regarding the performance of PSA in primary care, where most testing is done.
Article
Chemistry, Analytical
Zipeng Yin, Ling Zhu, Zijian Lv, Meijin Li, Dianping Tang
Summary: In this study, Zn2GeO4: Mn2+, Pr3+ (ZGOMP) nanorods were prepared and used as probes to detect prostate-specific antigen (PSA) with high selectivity and good analytical performance, making it an effective platform for clinical sample analysis. Hybritization chain reaction (HCR) and magnetic separation system were introduced for efficient signal amplification in the design.
Article
Medicine, General & Internal
Mari Carmen Bernal-Soriano, Lucy Anne Parker, Maite Lopez-Garrigos, Ildefonso Hernandez-Aguado, Luis Gomez-Perez, Juan-Pablo Caballero-Romeu, Maria Pastor-Valero, Nuria Garcia, Rocio Alfayate-Guerra, Blanca Lumbreras
Summary: Real world data shows that patients are still frequently exposed to overdiagnosis risk with a PSA potentially non-compliant with recommendations. Patients diagnosed with another neoplasm or non-consumers of toxic substances were more exposed, probably due to increased contact with doctors or health-seeking behaviour.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medical Laboratory Technology
Simona Ferraro, Davide Biganzoli, Roberta Simona Rossi, Franco Palmisano, Marco Bussetti, Enrica Verzotti, Andrea Gregori, Filippo Bianchi, Marco Maggioni, Ferruccio Ceriotti, Cristina Cereda, Gianvincenzo Zuccotti, Peter Kavsak, Mario Plebani, Giuseppe Marano, Elia Mario Biganzoli
Summary: Two nomograms were developed to predict the individual risk of high and low grade prostate cancer (PCa) based on tPSA and %f/tPSA. These nomograms can assist in the decision-making process and enhance the diagnostic capability for patients with ISUP >= 3.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Oncology
Danielle S. Bitterman, Ming-Hui Chen, Jing Wu, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff, Eric J. Small, Anthony V. D'Amico
Summary: This study found that low testosterone level at PSA failure in high-risk patients with PC treated with RT is associated with increased PCSM and ACM risk, and that higher PSAn is also associated with worse PCSM and ACM risk, especially in men with normal testosterone levels at PSA failure.
Article
Chemistry, Analytical
Junqi Zhao, Hao Ma, Yawen Liu, Baofeng Xu, Lina Song, Xiaoxia Han, Rui Liu, Chengyan He, Ziyi Cheng, Bing Zhao
Summary: The ratio of f-PSA% is more accurate in diagnosing prostate cancer and distinguishing it from other prostate diseases than the concentration of t-PSA alone. A SERS-based biosensor was developed in this study to simultaneously detect t-PSA and f-PSA. The biosensor combines Raman frequency shifts and intensities, simplifying traditional procedures for f-PSA% detection and showing great potential in highly reproducible and accurate diagnosis of prostate cancers.